RXO, Inc. (RXO) News
Track canonical SquawkNews coverage tagged to RXO, RXO, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 20 indexed stories across 12 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
RXO - Market Share Gains and Improved Profitability Drive Strong Second-Quarter Results for RXO
RXO - Market Share Gains and Improved Profitability Drive Strong Second-Quarter Results for RXO
EQUITY | Aug 06, 2026, 10:41 AM UTC
L
RXO to Present at Deutsche Bank Summit
RXO presenting at Deutsche Bank Chicago Industrials Summit
EQUITY | Aug 03, 2026, 12:41 PM UTC
H
CHRW shares fall 15% despite beating estimates
CHRW beats Q2 estimates, but shares fall 15%
EARNINGS | Jul 30, 2026, 03:02 PM UTC
L
RXO -5% after being downgraded to Sell from Hold at TD Cowen as sees the Montgomery Supreme Court decision and recent CHRW verdict as creati
RXO -5% after being downgraded to Sell from Hold at TD Cowen as sees the Montgomery Supreme Court decision and recent CHRW verdict as creating a tougher liability backdrop for the large truckload Brokers. RXO is among th
EQUITY | Jul 28, 2026, 01:44 PM UTC
H
Intuit downgrade, Intuitive Surgical upgraded: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled. Top 5 Upgrades: UBS upgraded Intuitive Surgical (I
EARNINGS | Jul 28, 2026, 01:35 PM UTC
L
RXO downgraded from Hold to Sell W/ $19 PT (from $24) @ TDCowen
RXO downgraded from Hold to Sell W/ $19 PT (from $24) @ TDCowen
EQUITY | Jul 28, 2026, 12:24 PM UTC
L
RXO Downgrade from Hold to Sell W/$19.00 PT (from $24.00) at TD Cowen
RXO Downgrade from Hold to Sell W/$19.00 PT (from $24.00) at TD Cowen
EQUITY | Jul 28, 2026, 11:49 AM UTC
L
RXO's valuation has become more attractive following the fallout from the Lipe V. Lupus Superior verdict, in which a jury awarded approximat
RXO's valuation has become more attractive following the fallout from the Lipe V. Lupus Superior verdict, in which a jury awarded approximately $604M against Lupus Superior, its driver, and CHRW @ Benchmark
EQUITY | Jul 28, 2026, 11:38 AM UTC
L
Top Downgrades: ACI: NEUTRAL @ UBS CAPR: NEUTRAL @ ROTH CAT: HOLD @ Erste CLX: HOLD @ Jefferies EBC: EQUAL WEIGHT @ Stephens INTU: HOLD @ TD
Top Downgrades: ACI: NEUTRAL @ UBS CAPR: NEUTRAL @ ROTH CAT: HOLD @ Erste CLX: HOLD @ Jefferies EBC: EQUAL WEIGHT @ Stephens INTU: HOLD @ TD Cowen LAUR: UNDERWEIGHT @ MS LEVI: EQUAL WEIGHT @ WFC MPLT: EQUAL WEIGHT @ MS P
EQUITY | Jul 28, 2026, 11:11 AM UTC
L
CHRW GXO Initiated with Market Outperforms - EXPD JBHT RLGT RXO initiated with Market Performs @ Citizens
CHRW GXO Initiated with Market Outperforms - EXPD JBHT RLGT RXO initiated with Market Performs @ Citizens
EQUITY | Jul 15, 2026, 11:16 AM UTC
L
CHRW RXO top picks in Transport preview - Near-term improvement from supply-side tightening as broader, multi-quarter recovery should become
CHRW RXO top picks in Transport preview - Near-term improvement from supply-side tightening as broader, multi-quarter recovery should become increasingly evident into the 2H-2026 @ Stifel
EQUITY | Jul 15, 2026, 10:54 AM UTC
L
JBHT CHRW RXO KNX Q226 Trucking/Logistics preview - positive KNX CHRW JBHT - promising pricing power @ SUSQ
JBHT CHRW RXO KNX Q226 Trucking/Logistics preview - positive KNX CHRW JBHT - promising pricing power @ SUSQ
EQUITY | Jul 14, 2026, 01:20 PM UTC
L
Apple, IBM downgraded: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled. Top 5 Upgrades: UBS upgraded FuelCell (FCEL) to Bu
EQUITY | Jul 14, 2026, 01:13 PM UTC
L
RXO new Outperform W/ $35 PT @ BMO
RXO new Outperform W/ $35 PT @ BMO
EQUITY | Jul 14, 2026, 11:04 AM UTC
L
RXO Initiate with an Outperform, $35 PT @ BMO
RXO Initiate with an Outperform, $35 PT @ BMO
EQUITY | Jul 13, 2026, 08:08 PM UTC
H
RXO Inc. price target raised to $18 from $16 at JPMorgan
JPMorgan raised the firm's price target on RXO Inc. to $18 from $16 and keeps an Underweight rating on the shares. The firm is updating estimates as part of its Q2 earnings preview for the transportation and logistics gr
EQUITY | Jul 10, 2026, 12:07 PM UTC
H
RXO Inc. price target raised to $30 from $24 at Citi
Citi raised the firm's price target on RXO Inc. to $30 from $24 and keeps a Neutral rating on the shares. Transports' Q2 earnings are likely to be among the strongest in years, as companies benefit from significantly tig
EARNINGS | Jul 09, 2026, 11:48 AM UTC
H
RXO Inc. resumed with an Equal Weight at Stephens
Stephens resumed coverage of RXO Inc. with an Equal Weight rating and $25 price target. The transport cycle is broadly improving, with more fundamental upside potential than downside risk ahead, its momentum should carry
EQUITY | Jul 08, 2026, 12:58 PM UTC
L
UBS Maintains Neutral on RXO, Raises Price Target to $26
UBS analyst Thomas Wadewitz maintains RXO (NYSE: RXO ) with a Neutral and raises the price target from $22 to $26.
EQUITY | Jun 30, 2026, 07:03 PM UTC
M
RXO: Barclays Raises Target
Barclays analyst Brandon Oglenski raises RXO price target to $28 and maintains Overweight rating
EQUITY | Jun 26, 2026, 07:58 PM UTC